180 related articles for article (PubMed ID: 37835531)
1. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
2. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
3. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
[TBL] [Abstract][Full Text] [Related]
4. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
6. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
Slatnick LR; Jimeno A; Gore L; Macy ME
Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
[TBL] [Abstract][Full Text] [Related]
8. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
9. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
11. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
[No Abstract] [Full Text] [Related]
12. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
13. Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma.
Zhu J; Wang J; Sun F; Zhen Z; Chen T; Lu S; Huang J; Zhang Y; Sun X
Front Oncol; 2022; 12():804310. PubMed ID: 35359419
[TBL] [Abstract][Full Text] [Related]
14. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman BJ; Li Y; Carlowicz C; Granger M; Cash T; Sadanand A; Somers K; Ranavaya A; Weiss BD; Choe M; Foster JH; Pinto N; Morgenstern DA; Rafael MS; Streby KA; Zeno RN; Mody R; Yazdani S; Desai AV; Macy ME; Shusterman S; Federico SM; Bagatell R
J Clin Oncol; 2023 Jan; 41(3):508-516. PubMed ID: 36206505
[TBL] [Abstract][Full Text] [Related]
15. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
16. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
Cheung IY; Cheung NV; Modak S; Mauguen A; Feng Y; Basu E; Roberts SS; Ragupathi G; Kushner BH
J Clin Oncol; 2021 Jan; 39(3):215-226. PubMed ID: 33326254
[TBL] [Abstract][Full Text] [Related]
17. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction.
Cupit-Link M; Federico SM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760578
[TBL] [Abstract][Full Text] [Related]
18. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Mora J; Chan GC; Morgenstern DA; Nysom K; Bear MK; Tornøe K; Kushner BH
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1627. PubMed ID: 35579862
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Mora J; Castañeda A; Colombo MC; Gorostegui M; Gomez F; Mañe S; Santa-Maria V; Garraus M; Macias N; Perez-Jaume S; Muñoz O; Muñoz JP; Barber I; Suñol M
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809255
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
